You can advertise here for as low as $0.025 (AUS) per click ! - Find out more
Findoz
found 1,460,000 results
Valeant Pharmaceuticals International | Home VALEANT PHARMACEUTICALS AND GLAXOSMITHKLINE ANNOUNCE WORLDWIDE COLLABORATION ... Valeant Pharmaceuticals Receives FDA Marketing. Approval for Cannabinoid ... www.valeant.com
Valeant Pharmaceuticals International | Home Valeant Locations. Dermatix® Efudex®/Efudix® Kinerase® Oxsoralen ... Valeant Pharmaceuticals Receives FDA Marketing. Approval for Cannabinoid Cesamet™ (CII) ... www.valeant.com/index.jspf
Valeant Pharmaceuticals International | R&D Portfolio The Valeant R&D Portfolio includes many development and marketed products across ... Valeant's research and development pipeline strategy comprises both new ... www.valeant.com/researchAndDevelopment/pipeline.jspf
Valeant Pharmaceuticals International | About Valeant | Home Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty ... Valeant is principally focused in the neurology and dermatology therapeutic ... www.valeant.com/aboutValeant/index.jspf
Valeant Pharmaceuticals International | Working At Valeant | Home Valeant Pharmaceuticals International is a progressive, exciting place to work ... At Valeant, we have a strong belief that the company's success coincides with ... www.valeant.com/workingAtValeant/index.jspf
Valeant Pharmaceuticals International | History Valeant signs licensing agreement for Canadian rights to (C)Xyrem® from Jazz Pharmaceuticals ... Valeant initiates taribavirin Phase 2b clinical study ... www.valeant.com/aboutValeant/history/index.jspf
Valeant Pharmaceuticals International | Retigabine Valeant Pharmaceuticals announced the publication of Phase 2 data for retigabine, ... Valeant is also in the process of evaluating retigabine as a sustained ... www.valeant.com/researchAndDevelopment/pipeline/retigabine.jspf
Valeant Pharmaceuticals International | Investor Relations | News ... VALEANT PHARMACEUTICALS TO ANNOUNCE 2008 SECOND QUARTER RESULTS ON AUGUST 11, 2008 ... VALEANT ANNOUNCES SUCCESSFUL COMPLETION OF RETIGABINE PHASE III EPILEPSY ... www.valeant.com/investorRelations/newsReleases.jspf
Valeant Pharmaceuticals International | News Releases | News Article Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet® ... "It is exciting that Valeant is initiating this trial to determine whether ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4190
Valeant Pharmaceuticals International | News Releases VALEANT PHARMACEUTICALS AND GLAXOSMITHKLINE ANNOUNCE WORLDWIDE COLLABORATION ... VALEANT ANNOUNCES SUCCESSFUL COMPLETION OF RETIGABINE PHASE III EPILEPSY PROGRAM ... www.valeant.com/mediaCenter/newsReleases.jspf
Valeant Pharmaceuticals International | Neurology Home Valeant recently acquired Xcel Pharmaceuticals, a privately held specialty ... The acquisition of Xcel expands Valeant's business in the U.S., enhances the ... www.valeant.com/products/neurology/index.jspf
Valeant Pharmaceuticals International | Infectious Disease Home Valeant is committed to marketing and developing effective medicines in the ... Valeant currently markets two infectious disease products, Ancotil®/Ancobon® ... www.valeant.com/products/infectiousDisease/index.jspf
Valeant Pharmaceuticals International | Neurology Valeant has rapidly expanded its neurological business over the past three years ... One of Valeant's products that provides therapies that fill this tremendous ... www.valeant.com/researchAndDevelopment/therapeuticArea/neurology.jspf
Valeant Pharmaceuticals International | History Valeant unveils Diastat® AcuDial™ for rapid, at-home treatment of epileptic seizures. Valeant sells manufacturing facility in Bryan, Ohio ... www.valeant.com/aboutValeant/history/history2005.jspf
Valeant Pharmaceuticals International | News Releases | News Article With the approval of Cesamet, Valeant is proud to offer a solution that will ... Last year, Valeant entered into an agreement with Par Pharmaceutical Companies, Inc. ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4158
Valeant Pharmaceuticals International | Taribavirin Valeant has begun enrolling patients in a Phase 2b clinical study for its ... Valeant posts protocol information for all ongoing Phase 2, 3, and 4 trials to ... www.valeant.com/researchAndDevelopment/pipeline/taribavirin.jspf
Valeant Pharmaceuticals International | CEO Message In many ways, 2006 was a life-changing year for Valeant Pharmaceuticals. ... One of Valeant's enduring strengths is its team of leaders and professionals and ... www.valeant.com/aboutValeant/ceoMessage.jspf
Valeant Pharmaceuticals International | History Valeant receives FDA approval of Zelapar® for patients with Parkinson's Disease ... Valeant sells manufacturing facility in Warsaw, Poland ... www.valeant.com/aboutValeant/history/history2006.jspf
Valeant Pharmaceuticals International | Dermatology Home Valeant is working to build a significant dermatology portfolio through both ... Valeant's dermatology sales force currently focuses on promoting Kinerase® and ... www.valeant.com/products/dermatology/index.jspf
Valeant Pharmaceuticals International | News Releases Valeant Pharmaceuticals to Present at Lazard Capital Markets Life Sciences Conference ... Valeant Pharmaceuticals Establishes 2004 Deferred Tax Valuation Allowance; ... www.valeant.com/mediaCenter/financialReports.jspf?year=2005
Valeant Pharmaceuticals International | Drug Development Valeant Pharmaceuticals is a specialty pharmaceutical organization that conducts ... Although Valeant is the sponsor of these studies, the success of a clinical ... www.valeant.com/researchAndDevelopment/drugDevelopment.jspf
Valeant Pharmaceuticals International | Investor Relations ... Valeant Pharmaceuticals International is committed to the highest standards of ... Valeant has implemented an active governance platform that includes such steps ... www.valeant.com/investorRelations/corporateGovernance.jspf
Valeant Pharmaceuticals| Mysoline Change Valeant is currently working to qualify an additional manufacturing site that ... Valeant received FDA approval to market this new tablet design on June 13th, ... www.valeant.com/mysoline/index.jspf
Valeant Pharmaceuticals International | News Releases | News Article Valeant Pharmaceuticals Unveils Diastat AcuDial for Safe, Rapid At-Home ... Timothy C. Tyson, Valeant's president and chief executive officer, said, ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4126
Valeant Pharmaceuticals International | News Releases | News Article Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe ... Valeant markets nabilone in the United States and Canada under the brand name ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4188
Valeant Pharmaceuticals International | News Releases | News Article The transaction significantly expands Valeant's business in North America and ... Valeant plans to market retigabine in the United States and key foreign markets ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=1236
Valeant Pharmaceuticals International | News Releases | News Article Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2 Study Data in Neurology ... Valeant is committed to developing innovative drugs for ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4195
Valeant Pharmaceuticals International | History Valeant announces advancement of research and development funding to accelerate ... Valeant makes strategic acquisition of Amarin Pharmaceuticals, Inc. ... www.valeant.com/aboutValeant/history/history2004.jspf
Valeant Pharmaceuticals International | News Releases | News Article Valeant will pay InterMune $113.5 million in cash upon closing, and subsequent ... The transaction was approved by Valeant's board of directors and is expected to ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf;j...FC623.frank?objectId=4136
Valeant Pharmaceuticals International | Financial Presentations Valeant Pharmaceuticals to Present at Bank of America 2006 Healthcare Conference ... Valeant Pharmaceuticals to Announce 2005 Fourth Quarter and Year Results ... www.valeant.com/investorRelations/financialReports.jspf?year=2006
Valeant Pharmaceuticals International | Infergen Valeant Pharmaceuticals is conducting a randomized, open-label, Phase 3 ... Valeant posts protocol information for all ongoing Phase 2, 3, and 4 trials to ... www.valeant.com/researchAndDevelopment/pipeline/infergen.jspf
Valeant Canada Limited - Home Valeant Canada is a specialty pharmaceutical company and is a subsidiary of ... Valeant Pharmaceuticals Signs Licensing Agreement for Canadian Rights to CXyrem® ... www.valeantcanada.com
Valeant Pharmaceuticals International | News Releases Valeant Pharmaceuticals Sells HEP-C Drug INFERGEN® to Three Rivers ... Valeant Pharmaceuticals Starts Phase 2 Retigabine Study for Treatment of Postherpetic Neuralgia ... www.valeant.com/mediaCenter/newsReleases.jspf?year=2007
Valeant Pharmaceuticals International | News Releases Valeant Receives Non-Approvable Letter from FDA for Labeling Application of ... Valeant Pharmaceuticals Agrees to Acquire Rights to Hep-C Drug Infergen® from ... www.valeant.com/mediaCenter/newsReleases.jspf?year=2005
Valeant Pharmaceuticals International | News Releases | News Article Valeant Pharmaceuticals Receives FDA Approval of Zelapar(R) for Patients with ... Zelapar is the second therapy Valeant has brought to market to help in the ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4163
Valeant Pharmaceuticals International | News Releases | News Article Valeant received approval for Cesamet, a synthetic cannabinoid, from the Food ... For product-related questions, call Valeant Pharmaceuticals at 1-877-361-2719. ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4171
Valeant Pharmaceuticals International | News Releases | News Article The addition of Valeant's portfolio will boost Invida's resources and enable us ... Valeant undertakes no obligation to update any of these forward-looking ... www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf?objectId=4232